Most Read Articles
Pearl Toh, 5 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
2 days ago
Nocturia is a risk factor for mortality, according to the results of the Nagahama Study, which boasts of a low incidence of missing data and high representation of the general population.
Audrey Abella, 14 Oct 2020
Despite a 90-percent cure rate after first treatment for children with acute lymphoblastic leukaemia (ALL), approximately 10–15 percent of patients with paediatric ALL will experience relapse. [Expert Rev Anticancer Ther 2017;17:725-736] A recent webinar on the current landscape of ALL highlighted the potential of immunotherapy for paediatric patients with relapsed or refractory ALL, thus providing hope for this high-risk patient group.

Cerebrovascular disease history ups mortality risk in COVID-19 patients

20 Sep 2020

A history of cerebrovascular disease increases the risk of mortality in patients with the novel coronavirus disease (COVID-19) by 2.78-fold when compared to those with other comorbidities or without underlying pathologies, reveal the results of a recent study.

The investigators performed a systematic review according to the PRISMA guidelines using the following databases: PubMed, Scopus, Embase, Medline, Lilacs, Science Direct, and EBSCO Host. Studies involving patients with a diagnosis of COVID-19 and a history of stroke were eligible for analysis.

Risk of bias was assessed using the Newcastle-Ottawa Scale, and experimental studies were evaluated using the ROBINS-I scale.

A total of 213 articles were identified, of which only seven met the eligibility criteria. Overall, 3,244 patients with COVID-19 were involved, of whom 198 had a history of cerebrovascular disease.

The meta-analysis of data revealed an increase in mortality among COVID-19 patients with a history of cerebrovascular disease (odds ratio, 2.78, 95 percent confidence interval, 1.42–5.46; p=0.007; I2, 49 percent) as compared to those with different comorbidities or those without underlying pathology.

Adequate heterogeneity was shown. In addition, an Egger test in a funnel plot was used to assess the presence of publication bias. Asymmetry was observed, indicating no publication bias. However, the presence of bias could neither be ruled out nor confirmed due to the low number of included studies.

“History of stroke has been associated with an increased risk of a new ischaemic stroke,” the investigators noted. “Several studies have indicated increased prevalence of strokes among coronavirus patients.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 5 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
2 days ago
Nocturia is a risk factor for mortality, according to the results of the Nagahama Study, which boasts of a low incidence of missing data and high representation of the general population.
Audrey Abella, 14 Oct 2020
Despite a 90-percent cure rate after first treatment for children with acute lymphoblastic leukaemia (ALL), approximately 10–15 percent of patients with paediatric ALL will experience relapse. [Expert Rev Anticancer Ther 2017;17:725-736] A recent webinar on the current landscape of ALL highlighted the potential of immunotherapy for paediatric patients with relapsed or refractory ALL, thus providing hope for this high-risk patient group.